Survival analysis of patient data suggested that CaV3.2 could be a potential differential biomarker in breast cancer subtypes where the overexpression of CaV3.2 was associated with poor disease outcomes in patients with ER-positive breast cancer, while CaV3.2 expression was positively correlated with patient survival after chemotherapy in patients with HER2 positive breast cancer [186]. This evidence concerns the gene ERBB2 and breast carcinoma.